Skip to content
value.today
Krystal Biotech, Inc. logo

Krystal Biotech, Inc.

Formerly Krystal Biotech, LLC

Total raised
$11 M
1 round on record
Latest round
$11 M
Aug 2017
First round on record
Aug 2017
Today
Went public
See the company page

Krystal Biotech, Inc. is listed today as Krystal Biotech, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Krystal Biotech, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2017$11 MNo. 1$10 to $50 million

Krystal Biotech, Inc.: Raise no. 1, Aug 2017

Investors in this round

16 investors had bought by the notice of Aug 18, 2017: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Krystal Biotech, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$11 M of $11 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Krish S. Krishnan · Executive Officer, Director
  • Dan M. Janney · Director
  • Dino M. Rossi · Director
  • Doug M. Norby · Director
  • Suma M. Krishnan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “The proceeds from the offering will be used for general working capital purposes including the payment of payroll. Officers listed in item 3 will be among the Issuer's employees who may receive a portion of regularly scheduled salary from such proceeds.”

Signed by Krish Krishnan, President, Secretary and Treasurer. Source: SEC Form D, newest notice filed Aug 18, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Krystal Biotech, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2017).

    SEC Form D · Aug 2017

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2017

That is all the official record says: Krystal Biotech, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Krystal Biotech, Inc. are on record.

Investors#

2 named in official filings. Open an investor to see everything it has backed.

Investors in Krystal Biotech, Inc.
InvestorKindAmountRoundRoleSource
Dino A. RossiPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2017)SEC Form 3
Sun Pharma (Netherlands) B.V.Othernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2017)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 16 investors.

Largest shareholders today

Institutions holding Krystal Biotech, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Krystal Biotech, Inc.
NameRoleNamed in
Krish S. KrishnanExecutive officerAug 2017
Dan M. JanneyDirectorAug 2017
Dino M. RossiDirectorAug 2017
Doug M. NorbyDirectorAug 2017
Krish S. KrishnanDirectorAug 2017
Suma M. KrishnanDirectorAug 2017

Went public since 2017. Its SEC number is that of a company listed on a stock exchange.